This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Paladin Labs Inc., Mcgill University, Other. Active years: 2014-2017.
Location History:
- Montréal, CA (2016)
- Montreal, CA (2014 - 2017)
Company Filing History:
2 out of 17 
1 out of 570 
1 out of 834,411 Years Active: 2014-2017
Title: Glen Deleavey: Innovator in Oligonucleotide Technologies
Introduction
Glen Deleavey is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of oligonucleotide technologies, holding a total of 4 patents. His work focuses on innovative methods for gene expression modulation and cancer treatment.
Latest Patents
Glen Deleavey's latest patents include groundbreaking inventions such as "Oligonucleotide duplexes comprising DNA-like and RNA-like nucleotides and uses thereof." This patent discloses novel oligonucleotide pairs that can form a duplex with one or more DNA-like nucleotides, such as 2'-substituted arabinonucleotides, in combination with RNA-like nucleotides. These duplexes have applications in silencing the expression of specific nucleic acids or genes using small interfering RNA technologies. Another significant patent is "Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas." This invention relates to compositions and therapeutic methods aimed at treating cancer, particularly malignant glioma, by utilizing antisense oligonucleotides or RNAs that inhibit tumor cell invasion.
Career Highlights
Throughout his career, Glen has worked with prominent organizations, including Paladin Labs Inc. and the Royal Institution for the Advancement of Learning/McGill University. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Glen has collaborated with esteemed colleagues such as Masad Jose Damha and Jonathan K Watts. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.
Conclusion
Glen Deleavey is a distinguished inventor whose work in oligonucleotide technologies has the potential to impact cancer treatment and gene expression modulation significantly. His contributions to the field are marked by his innovative patents and collaborations with leading experts.